Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents.
In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, Surbhi Sidana, MD, Stanford University, Stanford, CA, and Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, share some interesting insights into the optimal sequencing of bispecific antibodies and CAR-T cells in myeloma, highlighting data from recent clinical trials.
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?
ASH 2021: novel developments in MPNs
ASH 2021: evaluating the impact of screening for multiple myeloma precursor diseases
ASH 2021: the future of cell therapies in lymphoma
ASH 2021: highlights in CLL clinical trials
ASH 2021: updates in FLT3-mutated AML
The Lymphoma Sessions: post-ASH 2021
COSTEM: maintenance therapies for FLT3+ AML
COSTEM: the role of alloHSCT in ALL
SOHO 2021: amyloidosis treatment updates
IACH 2021: CAR-T in clinical practice
Unmet needs and recent updates in CML
IMW 2021: treatment-free intervals in multiple myeloma
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
EHA 2021: updates on novel agents for AML
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive